Browse by ["viewname_eprint_publisher" not defined]

F

Faehling, M. and Schumann, C. and Christopoulos, P. and Hoffknecht, P. and Alt, J. and Horn, M. and Eisenmann, S. and Schlenska-Lange, A. and Aries, S. P. and Sackmann, S. and Schuett, P. and Steger, F. and Christoph, D. (2020) Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP). In: ESMO Virtual Congress, SEP 19-OCT 18, 2020, ELECTR NETWORK.

S

Spoerl, Steffen and Gerken, Michael and Fischer, Rene and Mamilos, Andreas and Spoerl, Silvia and Wolf, Stefanie and Pohl, Fabian and Klingelhoeffer, Christoph and Ettl, Tobias and Reichert, Torsten E. and Spanier, Gerrit (2020) Lymphatic and vascular invasion in oral squamous cell carcinoma: Implications for recurrence and survival in a population-based cohort study. ORAL ONCOLOGY, 111: 105009. ISSN 1368-8375, 1879-0593

T

Tamaskovics, B. F. and Hecht, M. and Schubert, P. and Kallies, A. and Illmer, T. and Radke, J. and Koelbl, O. and Steger, F. and Brunner, T. B. and Roedel, C. and Fleischmann, M. and Reinacher-Schick, A. and Wingender, L. F. and Melchior, P. and Klautke, G. and Hintzen, U. and Gaipl, U. S. and Haussmann, J. and Budach, W. and Fietkau, R. (2023) Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial. ANNALS OF ONCOLOGY, 34. S593-S593. ISSN 0923-7534, 1569-8041

W

Wiegand, S. and Tamaskovics, B. F. and Brossart, P. and Kaftan, H. and Lewitzki, V. and Muenter, M. and Maschmeyer, G. and Rotter, N. and Stromberger, C. and Beck, M. and Gauler, T. C. and Schroeder, U. and Goerner, M. and Hautmann, M. and Guntinas-Lichius, O. and Hapke, G. and Dommerich, S. and Schmiedeknecht, A. and Wichmann, G. and Dietz, A. (2022) Postoperative adjuvant radiochemotherapy (aRCH) with cisplatin versus aRCH with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma: The ADRISK trial. ANNALS OF ONCOLOGY, 33 (Suppl7). S866. ISSN 0923-7534, 1569-8041